The AAV capsid directly governs which tissues the vector will transduce and determines the potential for pre-existing or treatment-emergent immunogenicity. An incorrect choice can lead to poor efficacy or unexpected toxicity, jeopardizing the entire IND-enabling program. A tailored selection process ensures the nonclinical data package accurately reflects the intended clinical activity.

Established serotypes often have well-characterized production processes, including protocols for AAV scalable suspension, which can streamline CMC development. Engineered capsids may offer superior performance but often require bespoke process development and the creation of novel analytical methods to ensure product quality, purity, and potency, impacting timelines and resources.

Our consultation is based on a deep library of preclinical data and manufacturing experience. For a venture focused on ocular therapies, we analyze data on capsids with high retinal transduction efficiency. For neuromuscular programs, we evaluate serotypes known for robust muscle tissue tropism. This tailored, science-led approach ensures the selected vector is optimized for the specific biological challenge.

The efficacy of an AAV-based therapeutic is directly tied to the biological properties of its capsid. Selecting the appropriate serotype is a complex scientific decision, balancing target tissue affinity and transduction efficiency against potential immunogenicity, manufacturing feasibility, and the regulatory path forward.

A successful program begins with a clear understanding of the target indication’s biological environment. This informs whether an established capsid with a well-documented performance profile is sufficient, or if a novel or engineered serotype is needed to achieve the desired therapeutic effect. Our approach is built on a foundation of historical data, enabling project teams to make informed decisions that minimize clinical risk.